Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 2/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478942 | 1.00 | ESR1 (0.39) | ESR1ESR2TLR8LPLLIPG | |
| SCHEMBL29414003 | 0.83 | NQO2 (0.46) | LPLLIPGNQO2CYP1A2JAK2 | |
| SCHEMBL21459066 | 0.83 | NQO2 (0.46) | LPLLIPGNQO2CYP1A2JAK2 | |
| SCHEMBL23043114 | 0.83 | CYP1A2 (0.49) | LPLLIPGCYP1A2JAK2BTK | |
| SCHEMBL30065387 | 0.81 | LPL (0.42) | LPLLIPGCYP1A2JAK2BTK | |
| SCHEMBL26260588 | 0.81 | EGFR (0.38) | LPLLIPGJAK2BTK | |
| SCHEMBL22555255 | 0.81 | LPL (0.42) | LPLLIPGCYP1A2JAK2BTK | |
| SCHEMBL29586872 | 0.80 | LPL (0.44) | LPLLIPGCYP1A2JAK2BTK | |
| SCHEMBL476862 | 0.80 | LPL (0.44) | LPLLIPGCYP1A2JAK2BTK | |
| SCHEMBL23796054 | 0.80 | PTPN1 (0.51) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210193931-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL COMPRISING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210193931-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL COMPRISING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE | TERT, ICOSLG, ELAVL1 | ESR1 371/4885ESR2 1070/4885TLR8 3178/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | ESR1 2484/4885ESR2 1348/4885TLR8 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.